New spectrum of side effects has emerged with the introduction of targeted therapies, including changes in parameters determining cardiovascular risk. Among other laboratory parameters, hyperuricemia and elevated Creactive protein (CRP) are associated with increased risk of cardiovascular disease. The aim of the present study was to investigate the changes of serum uric acid and CRP during the therapy with cetuximab, combined with 5-fluorouracil and high-dose folinic acid, in patients with metastatic colorectal carcinoma and the association of these changes with the outcome of the therapy. CRP and uric acid were determined using particle-enhanced immunoturbidimetric assay and uricase method, respectively. Measurements before and during the treatment were compared by Wilcoxon signed rank test, and comparison between survivors and non-survivors was performed by Mann-Whitney U test. Compared to baseline (pre-treatment) concentrations, serum uric acid was decreased significantly throughout the course of the combination treatment with irinotecan, 5-fluorouracil, highdose folinic acid and cetuximab. The decrease was evident early in the course of treatment. Serum CRP was also decreased significantly throughout the most of the course of therapy. The significant decrease of serum uric acid and CRP was evident already one week after the start of treatment. Serum CRP was significantly lower in patients who survived 12 months, but no difference of uric acid concentrations between survivors and non-survivors was found. A marked decrease of serum uric acid was observed during the combination therapy. High CRP was associated with poor prognosis, but no association between uric acid and prognosis was noted.
Introduction
The introduction of targeted agents has resulted in significant improvement of survival of patients with wide range of malignant disorders, including the most common cancers, e.g. breast carcinoma or colorectal carcinoma. In general, targeted agents are less toxic and better tolerated than conventional cytotoxic agents. On the other hand, a new spectrum of side effects has emerged with targeted therapies. Many of these side effects have only limited immediate impact on the patients, but may lead to significant chronic toxicity. Prominent among these side effects are changes in parameters determining cardiovascular risk, including hypertension, hyperlipidemia, impaired glucose tolerance and hypercholesterolemia. With improved patient survival, these side effects may be of concern because of increased long-term cardiovascular morbidity and mortality.
Hyperuricemia is associated with increased risk of cardiovascular disease, and higher cardiovascular risk is evident with increasing serum uric concentrations even in subject with levels within the normal range (1) . The increased cardiovascular risk associated with elevated uric acid levels is thought to be related to the effect of uric acid on the blood pressure. High concentrations of uric acid are postulated to be involved in the development of hypertension. Hyperuricemia was found to induce hypertension in an animal model by a renin-dependent mechanism (2). In another experimental study, renal arteriolopathy was caused by hyperuricemia (3). In patients with increased cardiovascular risk, hyperuricemia was associated with endothelial dysfunction (4), and increased risk of microalbuminuria was found in patients with pre-hypertension who had hyperuricemia (5) . Some of the effects of uric acid may be associated with the induction of inflammatory response as uric acid is known to induce the expression of C-reactive protein (6) . The serum concentration of C-reactive protein (CRP) is a well-defined risk factor of cardiovascular disease. CRP concentrations are increased in the serum of patients with atherosclerosis, and elevated serum CRP levels predict the risk of future cardiovascular event (7) (8) (9) . CRP concentrations are also increased in patients with advanced cancer, including metastatic colorectal carcinoma (10) .
Cetuximab is a chimeric antibody against epidermal growth factor receptor used in the therapy of advanced colorectal carcinoma. In a prospective clinical trial, cetuximab alone or in combination with irinotecan has demonstrated a significant clinical activity in patients with irinotecan-refractory metastatic colorectal carcinoma as monotherapy or in combination with irinotecan (11, 12) . Activity has also been demonstrated for cetuximab in combination with chemotherapy in the first line of treatment of metastatic colorectal carcinoma in patients with tumors not harboring K-ras mutation (13, 14) . The most common toxicity of cetuximab is skin rash (15) (16) (17) . Cetuximab is not known to increase blood pressure or affect lipid or glucose metabolism, and the only side effect related to cardiovascular risk identified so far is hypomagnesemia (18) .
The effect of cetuximab alone or in combination with cytotoxic chemotherapy on serum uric acid is unknown. Cytotoxic drugs may induce rapid tumor cell destruction resulting in high serum uric acid concentrations, in extreme cases manifesting as tumor lysis syndrome, but this condition is rare in patients with solid tumors (19) . Tumor lysis syndrome has also been described after treatment with single agent cetuximab (20) . On the other hand, a decrease of serum uric acid concentrations has been reported in patients treated with platinum-based chemotherapy (21) . Folinic acid administered as a part of combination regimens for colorectal carcinoma may inhibit the production of uric acid (22) , but little is known about the effects of pharmacologic doses of folinic acid on uricemia. The prevalence of hyperuricemia in cancer survivors treated with combined modality therapy is high (23) . In patients with metastatic colorectal carcinoma the changes of uric acid after combination treatment with cetuximab could be of significance as alterations of serum uric acid could modulate blood pressure changes induced by earlier or sequential treatment with bevacizumab.
The aim of the present study was to investigate the changes of serum uric acid and CRP during the therapy with cetuximab combined with 5-fluorouracilbased chemotherapy and high-dose folinic acid in patients with metastatic colorectal carcinoma. The association of these changes with the outcome of the therapy was also studied.
Patients and Methods
Fifty-one consecutive patients with metastatic colorectal carcinoma, 33 males and 18 females, aged (mean ± standard deviation) 61 ± 11 (range 32 -79) years were included in the study. Forty-nine patients were treated with the combination of cetuximab (loading dose 400 mg/m 2 , subsequently 250 mg/m (24), including one patient who received a modification of this regimen, one patient with hyperbilirubinemia has been treated with this regimen omitting irinotecan, and one patient was treated with cetuximab monotherapy. All patients have been previously treated with oxaliplatin. The patients signed informed consent. No specific instructions regarding the diet were given to the patients. Eight patients were treated with allopurinol.
Blood samples were taken before the start of therapy and then before each weekly infusion of cetuximab. CRP and uric acid were determined using particleenhanced immunoturbidimetric assay and uricase method, respectively, as commercially available on MODULAR analyzer (Hoffmann-La Roche, Basel, Switzerland).
Measurements before and during the treatment was compared by Wilcoxon signed rank test. The correlations were examined by Spearman correlation coefficient. Comparison between survivors and non-survivors was performed by Mann-Whitney U test. Survival was analyzed using the Kaplan-Meier method, and differences were evaluated by log-rank test. All statistical analyses were performed using NCSS software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
Compared to baseline (pre-treatment; visit 1) concentrations, serum uric acid was decreased significantly throughout the course of the combination treatment with cetuximab ( Figure 1 ). The decrease was evident early in the course of treatment. Serum CRP was also decreased significantly throughout most of the course of the therapy (Figure 2) . The significant decrease of serum uric acid and CRP was evident already one week after the start of treatment. The same results were observed after excluding patients treated with allopurinol (data not shown). No correlations between CRP and uric acid concentrations were observed.
Median CRP concentration was 22 mg/L. Patients with baseline CRP concentration below median had significantly longer survival compared to patients with CRP concentrations of 22 mg/L or above (median 18 vs. 9 months, p = 0.003). Median uric acid concentration was 329 µmol/L. There was no significant difference in survival between the patients with baseline uric concentrations below or above this median (median 12 vs. 11 months, p = 0.88). Median survival from the start of therapy in the present cohort of patients was 12 months. Differences in CRP or uric acid were compared in patients who survived 12 months or longer 
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and those who had shorter survival at the baseline and 5 subsequent visits. The comparison was limited to the first 6 visits because the number of evaluable patients decreased progressively thereafter, creating a potential bias. Serum CRP was significantly lower in patients who survived 12 months, but no difference of uric acid concentrations between survivors and non-survivors was found (Table 1) .
Discussion
Present data demonstrate a rapid and marked decrease of serum uric acid in patients with metastatic colorectal carcinoma treated with the combination of high-dose folinic acid, cytotoxic chemotherapy and cetuximab. Folinic acid (leucovorin; 5-formyltetrahydropteroylpolyglutamate) is administered to potentiate the inhibition of thymidylate synthase by 5-fluoro-2'-deoxyuridylate, the active metabolite of 5-fluorouracil. Folinic acid is also a potent inhibitor of xanthine oxidase, the enzyme catalyzing the production of uric acid (22) . Therefore, the administration of high-dose folinic acid may explain the dramatic fall in uricemia. It is possible that other components of the combination regimen also contributed to the marked decrease of uric acid. Because combination therapy was administered in almost all patients, it was not possible to discern whether the decrease of uricemia was due to cetuximab, irinotecan, 5-fluorouracil, high-dose folinic acid or the combination of these agents. Only one patient had single-agent cetuximab and a marked decrease of serum uric acid was also evident in this patient. Increased urinary loss was thought to be the cause of chemotherapy-induced hypouricemia observed after platinum-based chemotherapy (21) . In earlier investigations, anti-epidermal growth factor receptor therapy was demonstrated to cause alterations of renal tubular cell function resulting in increased urinary magnesium loss (25) , but it is not known whether increased urinary magnesium loss is accompanied by increased excretion of uric acid. A decreased food intake during chemotherapy may also play a role.
Although high-dose folinic acid in combination with 5-fluorouracil represents a backbone of regimens used to treat colorectal carcinoma and other gastrointestinal tumors, little is known about the effect of this therapy on serum uric acid. The clinical significance of the decrease of serum uric acid observed in these patients is uncertain. Although higher uric acid concentrations are a risk factor for the development of cardiovascular diseases, lowering serum uric acid could have both favorable and unfavorable effects. Despite the fact that uric acid is an important serum antioxidant, in different experimental systems it may have antioxidant as well as prooxidant activity (26) . Moreover, uric acid stimulates immune response, including tumor rejection (27) . Administration of uric acid has also been shown to improve endothelial dysfunction in patients with diabetes (28) . However, most evidence indicates that hyperuricemia is associated with increased risk of cardiovascular disorders. This negative impact of hyperuricemia on cardiovascular risk is probably linked to the induction of hypertension and endothelial dysfunction. Thus, chronic hyperuricemia has probably negative long-term effect on cardiovascular risk. From this perspective, the decrease of serum uric acid observed in the present Table 1 .: Serum uric acid and C-reactive protein in patients who survived more or less than 12 months.Shown is the mean ± standard error of the mean. cohort is reassuring. Despite the potential clinical significance of changes in uricemia during the combination therapy with high-dose folinic acid, this phenomenon has so far been unrecognized. The decrease of CRP observed in the present cohort is probably the result of tumor control by therapy. CRP reflects the inflammatory reaction induced by the tumor, and may behave as a tumor marker in this setting. Moreover, high CRP was associated with poor prognosis in the present cohort. The prognostic significance of acute phase response in patients with metastatic colorectal carcinoma has been described before (29) . In patients with metastatic colorectal carcinoma prognostic significance has also been reported for other indicators of systemic immune or inflammatory activation, e.g. neopterin (30) . The present study extends the association between acute phase response and poor prognosis to patients treated with cetuximab. The decrease of CRP would also be expected to have a favorable effect on long-term risk of cardiovascular disease in patients with metastatic colorectal carcinoma.
The life expectancy of patients with metastatic colorectal carcinoma treated in the third line setting is relatively short (11) . Therefore, the clinical impact of any changes of serum uric acid or CRP, irrespective of the direction in which these changes affect cardiovascular risk, would probably be limited in this patient population. However, the situation is different in the front line setting. The median survival after the start of first line therapy is around 2 years, and a significant proportion of patients survive five years or are even cured through combined-modality treatment (31) (32) (33) . Moreover, the effects of combined therapy on serum uric acid and CRP are probably not specific for the present regimen of combination with cetuximab, and would probably be observed with any combination regimen with highdose folinic acid. Recently, we have observed a decrease of serum CRP concentrations in patients with metastatic colorectal cancer treated with the combination of bevacizumab, oxaliplatin, 5-fluorouracil and folinic acid (34) . The long-term effect of changes of uric acid and CRP concentrations induced by the therapy on comorbid conditions should therefore be further investigated.
The finding of a marked decrease of serum uric acid is of possible significance for the management of hyperuricemia in these patients. The number of medications in cancer patients, including anticancer drugs, drugs used to treat the toxicity of treatment, e.g. antiemetics, pain medications or drugs used to treat comorbid disorders is often quite high, and any reduction in the number of pills the patient has to take daily is of obvious practical importance. A wait-and-see approach instead of prescribing allopurinol may be justified with regard to hyperuricemia in a patient with mild to moderate elevation of serum uric acid presenting for the treatment with cetuximab.
In conclusion, a marked decrease of serum uric acid was observed during the combination therapy with irinotecan, 5-fluorouracil, high-dose folinic acid and cetuximab. High CRP was associated with poor prognosis, but no association between uric acid and prognosis was noted.
